Peihua H. Lu
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 52 publications
Chimeric antigen receptor T-cell therapy in systemic lupus erythematosus: From B cell depletion to immune reprogramming.
Journal: Journal of translational autoimmunity
Published: June 09, 2026
Efficacy, Safety, and Kinetics of Naturally Selected Anti-CD7 CAR-T Cell Therapy in T-ALL/LBL With CNS Leukemia.
Journal: American journal of hematology
Published: April 17, 2026
Long-Term Outcomes of Second Allogeneic Transplantation Following CD7 CAR-T in Remission for T-Cell Acute Lymphoblastic Leukemia or Lymphoma.
Journal: Transplantation and cellular therapy
Published: March 16, 2026
The Eastern Cooperative Oncology Group Score Rather Than Donor Type Impacts Clinical Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Severe Aplastic Anemia Patients Aged 51-60 Years: A Retrospective Study From the Chinese Blood and Marrow Transplant Registry.
Journal: Clinical transplantation
Published: June 23, 2025
Immune reconstitution after CD7 CAR-T cell therapy for refractory/relapsed acute T-lymphoblastic leukaemia/lymphoblastic lymphoma (R/R T-ALL/LBL).
Journal: British journal of haematology
Published: June 19, 2025
SOHO State of the Art Updates and Next Questions | CD7 CAR-T Therapy for Treating CD7-Positive Hematological Malignancies: Clinical Advances and Future Directions.
Journal: Clinical lymphoma, myeloma & leukemia
Published: February 27, 2025
Efficacy and safety of BCMA nanobody CAR T-cell therapy in relapsed or refractory plasma cell myeloma.
Journal: Blood advances
Published: February 26, 2025
China Expert consensus on the application of metagenomic next-generation sequencing for the etiological diagnosis of infections in hematological disorders (2024).
Journal: Blood science (Baltimore, Md.)
Published: February 16, 2025
Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia.
Journal: Blood
Published: April 01, 2024
A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T-cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen receptor T-cell therapy.
Journal: British journal of haematology
Published: January 25, 2024
Last Updated: 09/26/2026